TScan Therapeutics Statistics
Total Valuation
TCRX has a market cap or net worth of $474.18 million. The enterprise value is $398.13 million.
| Market Cap | 474.18M |
| Enterprise Value | 398.13M |
Important Dates
The last earnings date was Monday, May 13, 2024, before market open.
| Earnings Date | May 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
TCRX has 52.86 million shares outstanding. The number of shares has increased by 291.63% in one year.
| Shares Outstanding | 52.86M |
| Shares Change (YoY) | +291.63% |
| Shares Change (QoQ) | +44.63% |
| Owned by Insiders (%) | 0.79% |
| Owned by Institutions (%) | 74.51% |
| Float | 25.44M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 32.01 |
| Forward PS | 28.15 |
| PB Ratio | 3.86 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 26.88 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.23, with a Debt / Equity ratio of 0.75.
| Current Ratio | 5.23 |
| Quick Ratio | n/a |
| Debt / Equity | 0.75 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -24.73 |
Financial Efficiency
Return on equity (ROE) is -61.10% and return on invested capital (ROIC) is -47.54%.
| Return on Equity (ROE) | -61.10% |
| Return on Assets (ROA) | -34.50% |
| Return on Capital (ROIC) | -47.54% |
| Revenue Per Employee | $96,182 |
| Profits Per Employee | -$628,552 |
| Employee Count | 154 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +151.54% in the last 52 weeks. The beta is 0.91, so TCRX's price volatility has been similar to the market average.
| Beta (1Y) | 0.91 |
| 52-Week Price Change | +151.54% |
| 50-Day Moving Average | 7.61 |
| 200-Day Moving Average | 5.21 |
| Relative Strength Index (RSI) | 64.41 |
| Average Volume (30 Days) | 209,227 |
Short Selling Information
The latest short interest is 397,970, so 0.75% of the outstanding shares have been sold short.
| Short Interest | 397,970 |
| Short Previous Month | 419,685 |
| Short % of Shares Out | 0.75% |
| Short % of Float | 1.56% |
| Short Ratio (days to cover) | 1.83 |
Income Statement
In the last 12 months, TCRX had revenue of $14.81 million and -$96.80 million in losses. Loss per share was -$1.18.
| Revenue | 14.81M |
| Gross Profit | 14.81M |
| Operating Income | -102.09M |
| Pretax Income | -96.80M |
| Net Income | -96.80M |
| EBITDA | -87.92M |
| EBIT | -93.04M |
| Loss Per Share | -$1.18 |
Balance Sheet
The company has $167.81 million in cash and $91.76 million in debt, giving a net cash position of $76.05 million or $1.44 per share.
| Cash & Cash Equivalents | 167.81M |
| Total Debt | 91.76M |
| Net Cash | 76.05M |
| Net Cash Per Share | $1.44 |
| Equity / Book Value | 122.97M |
| Book Value Per Share | 2.33 |
| Working Capital | 133.24M |
Cash Flow
In the last 12 months, operating cash flow was -$67.04 million and capital expenditures -$3.01 million, giving a free cash flow of -$70.05 million.
| Operating Cash Flow | -67.04M |
| Capital Expenditures | -3.01M |
| Free Cash Flow | -70.05M |
| FCF Per Share | -$0.74 |
Margins
Gross margin is 100.00%, with operating and profit margins of -689.22% and -653.50%.
| Gross Margin | 100.00% |
| Operating Margin | -689.22% |
| Pretax Margin | -653.50% |
| Profit Margin | -653.50% |
| EBITDA Margin | -593.57% |
| EBIT Margin | -628.11% |
| FCF Margin | -472.93% |
Dividends & Yields
TCRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -291.63% |
| Shareholder Yield | -291.63% |
| Earnings Yield | -20.41% |
| FCF Yield | -14.77% |
Analyst Forecast
The average price target for TCRX is $11.40, which is 26.95% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $11.40 |
| Price Target Difference | 26.95% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 20.99% |
| EPS Growth Forecast (5Y) | -2.41% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TCRX has an Altman Z-Score of 0.25 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.25 |
| Piotroski F-Score | 1 |